

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

DULOXETINE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
DULOXETINE HCL	DRIZALMA		46703	GPI-14	
	SPRINKLE		46713	(5818002510H120)	
			46714	(5818002510H130)	
			46715	(5818002510H140)	
				(5818002510H160)	

GUIDELINES FOR USE

- 1. Does the patient have **ONE** of the following diagnoses?
 - Major depressive disorder
 - Diabetic peripheral neuropathy
 - Fibromyalgia
 - Chronic musculoskeletal pain

If yes, continue to #2. If no, continue to #3.

- 2. Does the patient meet **ALL** of the following criteria?
 - The patient is 18 years of age or older
 - The patient had a trial of generic duloxetine
 - The patient cannot swallow duloxetine capsules

If yes, approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:

- 20 mg, 30 mg, 40 mg: #1 per day.
- 60 mg: #2 per day.

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

- 3. Does the patient have a diagnosis of generalized anxiety disorder and meet **ALL** of the following criteria?
 - The patient is 7 years of age or older
 - The patient had a trial of generic duloxetine
 - The patient cannot swallow duloxetine capsules

If yes, approve the requested strength for 12 months by GPID or GPI-14 with the following quantity limits:

- 20 mg, 30 mg, 40 mg: #1 per day.
- 60 mg: #2 per day.

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

2/17/2023 Page 1 of 2



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

DULOXETINE

GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **DULOXETINE** (**Drizalma Sprinkle**) requires the following rule(s) be met for approval:

- A. You have ONE of the following diagnoses:
 - 1. Major depressive disorder (a type of mental illness)
 - 2. Generalized anxiety disorder (a type of mental illness)
 - 3. Diabetic peripheral neuropathy (a type of nerve damage caused by high blood sugar)
 - 4. Fibromyalgia (a type of pain disorder)
 - 5. Chronic musculoskeletal pain (severe pain relating to muscles and bones)
- B. If you have major depressive disorder, diabetic peripheral neuropathy, fibromyalgia, or chronic musculoskeletal pain, approval also requires:
 - 1. You are 18 years of age or older
 - 2. You had a trial of generic duloxetine
 - 3. You cannot swallow duloxetine capsules
- C. If you have generalized anxiety disorder, approval also requires:
 - 1. You are 7 years of age or older
 - 2. You had a trial of generic duloxetine
 - 3. You cannot swallow duloxetine capsules

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Drizalma Sprinkle.

REFERENCES

 Drizalma Sprinkle [Prescribing Information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created:11/22

Commercial Effective: 04/01/23 Client Approval: 02/23 P&T Approval: 10/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

2/17/2023 Page 2 of 2